Cariprazine (Vraylar): Uses, Dosing, Side Effects, Interactions, and Safety

Forms & Strengths

Oral capsules: common strengths include 1.5 mg, 3 mg, 4.5 mg, and 6 mg, enabling tidy, once-daily titration across indications.

Dosing & Titration (label-based)

Never change doses without your prescriber. Because of the long half-life, dose changes take time to reach full effect.

Adjunctive MDD (Adults)

• Start1.5 mg once daily
• After ≥14 days, may increase to 3 mg once daily if needed
• Max3 mg/day (titrating faster than q14 days increased adverse events in trials)

Bipolar Depression (Adults)

• Start1.5 mg once daily
• After ≥14 days, may increase to 3 mg once daily if needed
• Max3 mg/day

Bipolar I: Acute Manic or Mixed Episodes (Adults)

• Day 11.5 mg once daily → Day 2: 3 mg
• Then adjust in 1.5–3 mg steps (as tolerated) across 3–6 mg/day
• Usual range3–6 mg/day; little evidence that >6 mg/day adds benefit vs risk

Schizophrenia (Adults)

• Day 11.5 mg once daily → Day 2: 3 mg
• Adjust by 1.5–3 mg increments to 1.5–6 mg/day (usual 3–6 mg/day)

Schizophrenia (Adolescents 13–17)

0.5–1 mg once daily initially, titrating to 2–4 mg/day as tolerated (follow PI for exact steps and timing).

Dose Adjustments: CYP & Organ Function

• CYP3A4 inhibitors (strong/moderate), reduce cariprazine dose; if the inhibitor is stopped, you may need to increaseback (under supervision). CYP3A4 inducers are not recommended with cariprazine.

• Hepatic/Renal impairment, follow PI for maximum doses in moderate–severe impairment.

How to Take It

Once daily, with or without food, at the same time each day for consistency. If you miss a dose, follow your prescriber’s instructions, don’t double. The long half-life means the effect of any change is delayed.

Common

Akathisia/restlessness, insomnia, nausea, headache, dizziness, fatigue, and constipation. In MDD adjunct trials, akathisia 7–10%, insomnia 9–10%, nausea 6–7% at labeled doses vs lower with placebo+ADT.

Metabolic & Movement

Weight gain and metabolic changes (glucose/lipids) are possible; clinicians usually monitor weight and labs. EPS(including akathisia, parkinsonism) can occur, especially with faster titration.

Boxed Warnings (Black Box)

• Increased mortality in elderly with dementia-related psychosis (not approved for dementia-related psychosis).

• Suicidal thoughts/behaviors with antidepressants in younger patients, relevant when using cariprazine for adjunctive MDD. Close monitoring during dose changes is essential.

Serious Risks (seek urgent care)

Neuroleptic Malignant Syndrome, tardive dyskinesia, orthostatic hypotension/falls, leukopenia/neutropenia, seizures, and angle-closure glaucoma, review the full PI and call your prescriber if red-flag symptoms appear.

Interactions

• CYP3A4-mediated interactions dominate:

  • Inhibitors (e.g., ketoconazole, clarithromycin) ↑ levels (dose reduction required.

  • Inducers (e.g., carbamazepine, rifampin) ↓ levels) co-use not recommended.

• Alcohol / cannabis can increase sedation/dizziness and impair judgment, clinicians usually recommend avoiding or minimizing.

Pharmacokinetics Snapshot

• Half-lifeabout 91 hours (active metabolite ~86 hours), which supports once-daily dosing and slow transitions when changing doses.
• Tmaxroughly 4 hours post-dose.
• Metabolismprimarily CYP3A4 (and to lesser extent CYP2D6).

Special Populations

• Pregnancy/Lactationweigh risks/benefits; consider the long half-life and potential neonatal adaptation risks with late-pregnancy antipsychotic exposure, discuss an individualized plan.
• Elderly with dementia-related psychosishigher mortality risk; cariprazine is not approved for that condition.